The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X).
Siu W. Lam
Research Funding - Roche
Steffen M. de Groot
No relevant relationships to disclose
Aafke H. Honkoop
No relevant relationships to disclose
Nienke M. Nota
No relevant relationships to disclose
A. Jager
No relevant relationships to disclose
Ankie M.T. van der Velden
No relevant relationships to disclose
Monique M.E.M. Bos
No relevant relationships to disclose
Sabine C. Linn
Consultant or Advisory Role - Roche
Research Funding - Roche
Other Remuneration - Roche
J. Van Den Bosch
No relevant relationships to disclose
Judith R. Kroep
No relevant relationships to disclose
J. J. Braun
No relevant relationships to disclose
Richard R. de Haas
No relevant relationships to disclose
Carolien H. Smorenburg
No relevant relationships to disclose
Hiltje de Graaf
No relevant relationships to disclose
Johanna Elisabeth A. Portielje
No relevant relationships to disclose
Maartje Los
No relevant relationships to disclose
Domingo de Gooyer
No relevant relationships to disclose
Harm van Tinteren
No relevant relationships to disclose
Epie Boven
Research Funding - Roche